Cancer Cell Membrane-Coated Nanoparticles

Cancer cell membrane-coated nanoparticles (CCM-NPs) offer enhanced tumor targeting, immune evasion, and improved therapeutic efficacy. Cancer cell membrane-coated nanoparticles leverage tumor-associated antigens and homotypic targeting mechanisms to preferentially accumulate at tumor sites, enhancing therapeutic precision. This study addresses these gaps by systematically evaluating CCM-NPs alongside other membrane types, elucidating their high drug loading efficiency (85–95%), tumor targeting capability, and moderate circulation half-life (15–25 hours). Importantly, CCM-NPs demonstrate substantial tumor growth inhibition (65–80%). The novelty lies in harnessing the homologous binding and antigen presentation capacities of cancer membranes to improve targeted delivery. The metastasis suppression (45–65%), and survival benefits (up to 3.5-fold increase) in preclinical cancer models, outperform conventional nanoparticles. Overall, this work provides a rationale for advancing CCM-NPs, aiming to overcome clinical limitations.